Tessera Therapeutics
2018
United States of America based
$230 M
https://tesseratherapeutics.com/
Tessera Therapeutics is pioneering Gene Writing—a revolutionary genome engineering technology that is designed to write and rewrite small and large therapeutic messages into the genome, thereby curing diseases at their source
Tessera Therapeutics raised over $230 million in the Series B round from an impressive group of investors to accelerate the research and development of their technology platform
gene editing gene writing
Technologies
Gene Therapy StartupsPosts Mentioning This Company
R&D Platform
In recent years, we’ve made extraordinary leaps in genetic medicine, with two pillar technologies emerging: gene therapy and gene editing. While these methods represent major advancements, they are not without significant limitations.
Nature has evolved a better way to alter genes— by harnessing this biology we can write and rewrite DNA into the genome.
Pipelines
No pipelines published yet
Products
Services
No services posted yet
